Skip to main content
C

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Filings indexed 503 across all filing types
Latest filing 2025-08-26 Regulatory Filings
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Placement Participant Update 2 pages 134.3KB
Regulatory Filings
2025-08-26 English
Update - Proposed issue of securities - CMB 5 pages 18.3KB
Regulatory Filings
2025-08-26 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 357.6KB
Regulatory Filings
2025-07-30 English
Cambium Bio Raises A$2.12 million 3 pages 128.6KB
Regulatory Filings
2025-07-29 English
Proposed issue of securities - CMB 5 pages 18.4KB
Regulatory Filings
2025-07-29 English
Cambium Bio Clears FDA Regulatory Hurdles 2 pages 115.3KB
Regulatory Filings
2025-07-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.